SCHEMBL1458910

SCHEMBL1458910

COC(=O)C(Cc1ccccc1)NC(=O)Cc1cc(C)cc(C)c1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.63
ATM Q13315 2/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
ALDH1A1 P00352 3/20 0.57
LMNA P02545 2/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
THRB P10828 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
HSD17B10 Q99714 1/20 0.56
POLB P06746 3/20 0.55
GAA P10253 1/20 0.54
RAB9A P51151 1/20 0.54
KLK5 Q9Y337 1/20 0.54
GLA P06280 1/20 0.53
HDAC1 Q13547 2/20 0.53
HDAC6 Q9UBN7 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1458909 1.00 TACR1 (0.63) TACR1ATML3MBTL1ALDH1A1LMNA
SCHEMBL4156601 0.90 ATM (0.65) ATMALDH1A1LMNAMEN1KMT2A
SCHEMBL4156603 0.90 ATM (0.65) ATMALDH1A1LMNAMEN1KMT2A
SCHEMBL14205009 0.89 ATM (0.69) ATML3MBTL1ALDH1A1LMNAMEN1
SCHEMBL14816081 0.89 ATM (0.69) ATML3MBTL1ALDH1A1LMNAMEN1
SCHEMBL1458962 0.87 TACR1 (0.56) TACR1L3MBTL1KMT2A
SCHEMBL1459337 0.87 TACR1 (0.56) TACR1L3MBTL1KMT2A
SCHEMBL1458913 0.87 TACR1 (0.56) TACR1L3MBTL1KMT2A
SCHEMBL20514956 0.84 ATM (0.55) ATMALDH1A1LMNAMEN1KMT2A
SCHEMBL20514957 0.84 ATM (0.55) ATMALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822698-B2 Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the Met family UNIVERSITE D'AIX-MARSEILLE (FR) 2014-09-02 US disclosed
US-20130085143-A1 AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY UNIVERSITE D'AIX-MARSEILLE (FR) 2013-04-04 US disclosed
EP-2483280-A1 NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY Université d'Aix-Marseille (FR) 2012-08-08 EP disclosed
EP-2305688-A1 Novel aminoacids derivatives, their process of preparation and their therapeutical uses as MET inhibitors Université de la Méditerranée - Aix-Marseille II (FR) 2011-04-06 EP disclosed
WO-2011036303-A1 NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II (FR) 2011-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085143-A1 AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY MET, HGFAC, HRAS TACR1 4287/4885ATM 191/4885L3MBTL1 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.